Top Markets
Coin of the day
CMIC HOLDINGS Co., Ltd. CMIC HOLDINGS Co., Ltd.

CMIC HOLDINGS Co., Ltd.

2309
Kedudukan dalam Saham #16496
Based in Tokyo, Japan, CMIC HOLDINGS Co., Ltd. serves as a leading provider of... Based in Tokyo, Japan, CMIC HOLDINGS Co., Ltd. serves as a leading provider of extensive services to the pharmaceutical industry within Japan. Its operational framework is structured across five strategic segments: Contract Research Organization (CRO), Contract Development and Manufacturing Organization (CDMO), Contract Sales Organization (CSO), Healthcare, and Innovative Pharma Model. Through its CRO capabilities, the company orchestrates comprehensive clinical trial services, encompassing everything from clinical operations, precise data management, and medical writing to patient recruitment, pharmacovigilance, project leadership, and stringent audit and quality assurance, alongside expert statistical analysis. Additionally, it offers critical consulting expertise in areas like clinical site network development, drug formulation, health economics, market entry strategies, and regulatory navigation, including advice on national health insurance pricing for medical devices and in vitro diagnostics. CMIC's CDMO division is instrumental in drug development and manufacturing, handling commercial supply, contract development, investigational product manufacturing, and specialized tasks such as packaging, labeling, release and stability testing, and technology transfer, bolstered by advanced formulation, process, and analytical development services. The company also operates sophisticated laboratory facilities, delivering bioanalysis, GLP/GMP analysis, and studies on biomarkers, large and small molecules, oligonucleotides, and conducting thorough toxicity, safety pharmacology, and non-clinical assessments. Within its Healthcare segment, CMIC focuses on patient and healthcare support, offering innovative solutions like drug adherence programs, specialized health platforms (harmo, Helc+), extensive prescription drug databases, and personalized health checks (selcheck). Beyond these, its portfolio includes post-marketing surveillance, self-inspection, regulatory affairs consulting, regulatory submissions and correspondence, sales and marketing support, and efficient clinical research coordinating and site management services. Demonstrating its commitment to innovation, CMIC HOLDINGS Co., Ltd. has entered into a strategic partnership with Science 37, Inc. to advance the adoption of decentralized clinical trials, thereby accelerating the progress of new treatment development. The company was originally established in 1985.
Harga Saham
$17.25
Disegerakkan terakhir: 2024-03-27
Modal Pasaran
$291.27M
Perubahan (1 hari)
-0.46%
Perubahan (1 tahun)
0.00%
Negara
JP
Perdagangan CMIC HOLDINGS Co., Ltd. (2309)

Kategori

Nisbah P/E bagi CMIC HOLDINGS Co., Ltd. (2309)
Nisbah P/E pada 2026 TTM: 0
Menurut laporan kewangan dan harga saham terkini CMIC HOLDINGS Co., Ltd., nisbah P/E semasa (TTM) ialah 0. Pada akhir 2026, syarikat mempunyai nisbah P/E sebanyak 0.
Sejarah nisbah P/E bagi CMIC HOLDINGS Co., Ltd. dari 2026 hingga 2026
Nisbah P/E pada akhir setiap tahun
Tahun Nisbah P/E Ubah
Tidak cukup data untuk tarikh yang disediakan.
Nisbah P/E untuk syarikat serupa atau pesaing
Syarikat Nisbah P/E Perbezaan Nisbah P/E Negara
33.14 -
US
37.80 -
US
- -
CN
-236.74 -
US
39.09 -
US
Cara membaca nisbah P/E

Nisbah Harga/Perolehan (P/E) mengukur hubungan antara harga saham syarikat dan pendapatan sesaham.
P/E yang rendah tetapi positif menunjukkan syarikat menjana keuntungan tinggi berbanding dengan penilaian semasa dan mungkin dinilai rendah. P/E negatif yang tinggi (hampir 0) menunjukkan kerugian besar.

Syarikat dengan P/E melebihi 30 atau negatif biasanya dilihat sebagai "saham pertumbuhan", bermaksud pelabur menjangkakan pertumbuhan atau keuntungan masa depan.

Syarikat dengan P/E positif di bawah 10 biasanya dianggap sebagai "saham nilai", bermaksud syarikat sudah menguntungkan dan tidak dijangka berkembang pesat.